Literature DB >> 15098012

Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas.

Onder Onguru1, Bernd W Scheithauer, Kalman Kovacs, Sergio Vidal, Long Jin, Shuya Zhang, Katharina H Ruebel, Ricardo V Lloyd.   

Abstract

Epidermal growth factor receptor plays an important role in the pathogenesis of many malignancies. Various growth factors, including epidermal growth factor receptor, have been shown to influence pituitary tumor growth and differentiation. To analyze the role of epidermal growth factor receptor in pituitary tumor development, we examined normal pituitaries (n=8), pituitary adenomas (n=158), and pituitary carcinomas (n=7) for expression of epidermal growth factor receptor protein and messenger RNA using tissue microarrays and RT-PCR. We also examined (a) the expression of phospho-epidermal growth factor receptor, the activated form of epidermal growth factor receptor, in pituitary tumors and normal pituitaries by immunohistochemistry and (b) the effects on epidermal growth factor receptor expression of treating pituitary cells (HP75 cell line) with epidermal growth factor. Epidermal growth factor receptor and the phosphorylated variant expression were present in normal pituitary cells. Epidermal growth factor receptor messenger RNA was also detected in normal pituitaries, pituitary adenomas, and carcinomas by in situ hybridization and RT-PCR. Most pituitary adenomas showed expression of epidermal growth factor receptor and the phosphorylated variant. Nonfunctional adenomas showed higher levels of expression of epidermal growth factor receptor (76 vs 34%) and of phospho-epidermal growth factor receptor (26 vs 8%) as compared to functional adenomas. Five of seven pituitary carcinomas showed strong expression of both epidermal growth factor receptor and phospho-epidermal growth factor receptor. When a human pituitary cell line (HP75) was cultured in the presence of epidermal growth factor receptor, there was an increase in the levels of both epidermal growth factor receptor and phospho-epidermal growth factor receptor after 5 h of treatment, thus confirming that epidermal growth factor receptor signaling was active in pituitary tumors. These results indicate that activated epidermal growth factor receptor is expressed in pituitary adenomas and carcinomas. Higher levels in pituitary carcinomas suggest a role in pituitary tumor progression. Copyright 2004 USCAP, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098012     DOI: 10.1038/modpathol.3800118

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

1.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

2.  Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.

Authors:  George Vlotides; Emily Siegel; Ines Donangelo; Shiri Gutman; Song-Guang Ren; Shlomo Melmed
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 3.  Pathogenesis of non-functioning pituitary adenomas.

Authors:  Maria Chiara Zatelli
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 4.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

5.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

Authors:  Hidenori Fukuoka; Odelia Cooper; Anat Ben-Shlomo; Adam Mamelak; Song-Guang Ren; Dave Bruyette; Shlomo Melmed
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

6.  A new medical therapy for Cushing disease?

Authors:  Fredric E Wondisford
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

7.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

8.  Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.

Authors:  Shi-Qi Cheng; Heng-Yi Fan; Xin Xu; Wei-Wei Gao; Shi-Gang Lv; Min-Hua Ye; Miao-Jing Wu; Xiao-Li Shen; Zu-Jue Cheng; Xin-Gen Zhu; Yan Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

9.  Heregulin regulates prolactinoma gene expression.

Authors:  George Vlotides; Odelia Cooper; Yen-Hao Chen; Song-Guang Ren; Yona Greenman; Shlomo Melmed
Journal:  Cancer Res       Date:  2009-04-28       Impact factor: 12.701

10.  HMGA1a recognition candidate DNA sequences in humans.

Authors:  Takayuki Manabe; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.